Skip to content
2000
Volume 25, Issue 14
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

Background

Gaucheromas, pseudotumors composed of Gaucher cells, are rare complications of Gaucher’s Disease (GD). They are usually seen in patients receiving enzyme replacement. Surgery is generally not recommended for these benign masses in treatment management. Most patients treated with Enzyme Replacement Therapy (ERT) show organ enlargement and improvement in laboratory values. In our case, no change in the size of the lesions was observed despite 4 years of standard dose ERT.

Case presentation

A 27-year-old female, not having a known chronic disease and occasionally consulting doctors due to bone pain, weakness, and fatigue, visited the emergency department with the complaint of a nosebleed four years ago. The patient was found to have hepatosplenomegaly in physical examination and was referred to the hematology clinic because of pancytopenia. According to the physical examination and laboratory results, the desired leukocyte glucocerebrosidase level was 0.4 micromol/lt/hour (normal range > 2.5). Homozygous mutations of p.L483P and L483P were observed in genetic tests. Based on these results, the patient was diagnosed with GD. Although the patient received regular weekly treatment for 4 years, no significant change was observed in the spleen size. The patient was admitted to the hospital in April 2022 with complaints of abdominal fullness and indigestion. Her quality of life was deteriorating due to massive splenomegaly. A splenectomy was performed on the patient. In our case, splenic gaucheroma, a rare complication of Gaucher’s disease, was found to be present.

Conclusion

These masses, which are a rare complication of GD, have started to be better recognized by radiologists and clinicians thanks to the case series shared, and it is clear that there is a need for standardization and further research in this field. With an increase in the number of cases and experiences in this field, there will inevitably be different and new developments in follow-up and treatment approaches.

This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303325860241023063241
2025-01-08
2025-12-20
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/25/14/EMIDDT-25-14-06.html?itemId=/content/journals/emiddt/10.2174/0118715303325860241023063241&mimeType=html&fmt=ahah

References

  1. WeinrebN.J. CameloJ.S.Jr CharrowJ. McClainM.R. MistryP. BelmatougN. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.Mol. Genet. Metab.2021132210011110.1016/j.ymgme.2020.12.29533485799
    [Google Scholar]
  2. StirnemannJ. BelmatougN. CamouF. SerratriceC. FroissartR. CaillaudC. LevadeT. AstudilloL. SerratriceJ. BrassierA. RoseC. Billette de VillemeurT. BergerM. A review of Gaucher disease pathophysiology, clinical presentation and treatments.Int. J. Mol. Sci.201718244110.3390/ijms1802044128218669
    [Google Scholar]
  3. NalysnykL. RotellaP. SimeoneJ.C. HamedA. WeinrebN. Gaucher disease epidemiology and natural history: a comprehensive review of the literature.Hematology2017222657310.1080/10245332.2016.124039127762169
    [Google Scholar]
  4. OrcelP. JavierR-M. Gaucher disease.Rheumatology.Elsevier201517051710
    [Google Scholar]
  5. BarisH.N. CohenI.J. MistryP.K. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.Pediat. endocrinol. rev. PER.20141272
    [Google Scholar]
  6. DavidsonB.A. HassanS. GarciaE.J. TayebiN. SidranskyE. Exploring genetic modifiers of Gaucher disease: The next horizon.Hum. Mutat.201839121739175110.1002/humu.2361130098107
    [Google Scholar]
  7. IvanovaM. LimgalaR.P. ChangsilaE. KamathR. IoanouC. Goker-AlpanO. Gaucheromas: When macrophages promote tumor formation and dissemination.Blood Cells Mol. Dis.20186810010510.1016/j.bcmd.2016.10.01827839983
    [Google Scholar]
  8. IvanovaM.M. ChangsilaE. TurgutA. Goker-AlpanO. Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines.Am. J. Transl. Res.201810113750376130662625
    [Google Scholar]
  9. UzenR. BayramF. DursunH. KardasF. CakirM. CucerN. EkenA. Donmez-AltuntasH. Characterization of peripheral blood T follicular helper (TFH) cells in patients with type 1 Gaucher disease and carriers.Blood Cells Mol. Dis.202310010272810.1016/j.bcmd.2023.10272836738539
    [Google Scholar]
  10. UzenR. BayramF. DursunH. KardasF. Altın-CelikP. CakirM. EkenA. CucerN. Donmez-AltuntasH. Oxidative and chromosomal DNA damage in patients with type I Gaucher disease and carriers.Clin. Biochem.2023111263110.1016/j.clinbiochem.2022.10.00936257477
    [Google Scholar]
  11. YanoS. MoseleyK. MahajanN. WarrenM. VachonL. Large mesenteric gaucheroma responds to substrate reduction therapy: A New Management of Gaucheromas. J. Pediat. Genet.2022111475010.1055/s‑0040‑1714699
    [Google Scholar]
  12. LimA.K. VellodiA. McHughK. Mesenteric mass in a young girl - an unusual site for Gaucher’s disease.Pediatr. Radiol.200232967467610.1007/s00247‑002‑0761‑012195308
    [Google Scholar]
  13. KorulaS. OwensP. CharltonA. BhattacharyaK. Rare case of hepatic Gaucheroma in a child on enzyme replacement therapy.JIMD Rep.20163210110410.1007/8904_2016_56227334896
    [Google Scholar]
  14. TsengS.Y. NiuD.M. ChuT.H. YehY.C. HuangM.H. YangT.F. LiaoH.C. ChiangC.C. HoH.C. SoongW.J. YangC.F. Very rare condition of multiple Gaucheroma: A case report and review of the literature.Mol. Genet. Metab. Rep.20192010047310.1016/j.ymgmr.2019.10047331193028
    [Google Scholar]
  15. AşantoğrolF. DursunH. CangerE.M. BayramF. Clinical and radiological evaluation of dentomaxillofacial involvement in Type I Gaucher disease.Oral Radiol.202238221022310.1007/s11282‑021‑00546‑234302573
    [Google Scholar]
  16. RegenboogM. BohteA.E. AkkermanE.M. StokerJ. HollakC.E.M. Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment.Br. J. Haematol.2017179463564710.1111/bjh.1491528905365
    [Google Scholar]
  17. RamaswamiU. MengelE. BerrahA. AlSayedM. BroomfieldA. DonaldA. seif El DeinH.M. FreisensS. HwuW.L. PeterschmittM.J. YooH.W. AbdelwahabM. Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma.Mol. Genet. Metab.2021133433534410.1016/j.ymgme.2021.06.00934229967
    [Google Scholar]
/content/journals/emiddt/10.2174/0118715303325860241023063241
Loading
/content/journals/emiddt/10.2174/0118715303325860241023063241
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test